文献速递糖尿病骨质疏松与钙磷/甲状旁腺

血清脂联素可预测2型糖尿病患者的骨折风险:福冈糖尿病登记研究

Serum adiponectin predicts fracture risk in individuals with type 2 diabetes: the Fukuoka Diabetes Registry.
PubMed 文献 · Diabetologia · 2017-07-18

该多中心前瞻性研究纳入4869例2型糖尿病患者(平均年龄65岁),中位随访5.3年,评估血清脂联素与骨折风险的关系。结果显示,对数转换后血清脂联素每增加1个标准差,绝经后女性任何部位骨折的年龄校正HR为1.27(95%CI 1.15,1.40),男性为1.22(95%CI 1.08,1.38);主要骨质疏松性骨折(MOFs)的HR分别为1.35(95%CI 1.17,1.55)和1.40(95%CI 1.15,1.71)。高脂联素血症(≥20 μg/ml)与MOFs风险升高相关,绝经后女性HR为1.72(95%CI 1.19,2.50),男性为2.19(95%CI 1.23,3.90)。

要点

  • 在2型糖尿病患者中,较高的血清脂联素水平与任何部位骨折风险升高显著相关。
  • 血清脂联素水平升高与主要骨质疏松性骨折风险升高显著相关,包括绝经后女性。
  • 高脂联素血症对主要骨质疏松性骨折的人群归因危险度百分比与年龄≥70岁或女性性别相当。

核心结论

  • 在2型糖尿病患者(包括绝经后女性)中,较高的血清脂联素水平与任何部位骨折风险升高及主要骨质疏松性骨折风险升高显著相关。

研究设计与样本

  • 本研究为多中心前瞻性研究,数据来自福冈糖尿病登记研究,旨在探讨现代治疗对糖尿病患者预后的影响。
  • 共随访4869例2型糖尿病患者(平均年龄65岁),包括1951例绝经后女性(定义为自报闭经超过1年)和2754例男性,中位随访5.3年。
  • 主要结局为任何部位骨折和主要骨质疏松性骨折(MOFs)。

主要发现

  • 随访期间,682例参与者发生任何部位骨折,277例发生主要骨质疏松性骨折。
  • 对数转换后血清脂联素每增加1个标准差,绝经后女性任何部位骨折的年龄校正HR为1.27(95%CI 1.15,1.40),男性为1.22(95%CI 1.08,1.38)。
  • 对数转换后血清脂联素每增加1个标准差,绝经后女性主要骨质疏松性骨折的年龄校正HR为1.35(95%CI 1.17,1.55),男性为1.40(95%CI 1.15,1.71)。
  • 高脂联素血症(≥20 μg/ml)与主要骨质疏松性骨折风险升高相关,绝经后女性HR为1.72(95%CI 1.19,2.50),男性HR为2.19(95%CI 1.23,3.90)。
  • 高脂联素血症对主要骨质疏松性骨折的人群归因危险度百分比与年龄≥70岁或女性性别相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Serum adiponectin has been reported to impact upon fracture risk in the general population. Although type 2 diabetes is associated with increased fracture risk, it is unclear whether serum adiponectin predicts fractures in individuals with type 2 diabetes. The aim of the study was to prospectively investigate the relationship between serum adiponectin and fracture risk in individuals with type 2 diabetes. METHODS: In this study, data was obtained from The Fukuoka Diabetes Registry, a multicentre prospective study designed to investigate the influence of modern treatments on the prognoses of patients with diabetes mellitus. We followed 4869 participants with type 2 diabetes (mean age, 65 years), including 1951 postmenopausal women (defined as self-reported amenorrhea for >1 year) and 2754 men, for a median of 5.3 years. The primary outcomes were fractures at any site and major osteoporotic fractures (MOFs). RESULTS: During the follow-up period, fractures at any site occurred in 682 participants, while MOFs occurred in 277 participants. Age-adjusted HRs (95% CIs) of any fracture and MOFs for 1 SD increment in log e -transformed serum adiponectin were 1.27 (1.15, 1.40) and 1.35 (1.17, 1.55) in postmenopausal women and 1.22 (1.08, 1.38) and 1.40 (1.15, 1.71) in men, respectively. HRs (95% CIs) of MOFs for hyperadiponectinaemia (≥ 20 μg/ml) were 1.72 (1.19, 2.50) in postmenopausal women and 2.19 (1.23, 3.90) in men. The per cent attributable risk of hyperadiponectinaemia for MOFs was as high as being age ≥70 years or female sex. CONCLUSIONS/INTERPRETATION: Higher serum adiponectin levels were significantly associated with an increased risk of fractures at any site and with an increased risk of MOFs in individuals with type 2 diabetes, including postmenopausal women.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Komorita Y, Iwase M, Fujii H, et al. Serum adiponectin predicts fracture risk in individuals with type 2 diabetes: the Fukuoka Diabetes Registry. Diabetologia. 2017. PMID: 28721438. doi:10.1007/s00125-017-4369-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。